Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Aujla, Amandeep, Aujla, Ravijot, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458768/
https://www.ncbi.nlm.nih.gov/pubmed/31011424
http://dx.doi.org/10.1186/s40364-019-0160-4
_version_ 1783410078649417728
author Aujla, Amandeep
Aujla, Ravijot
Liu, Delong
author_facet Aujla, Amandeep
Aujla, Ravijot
Liu, Delong
author_sort Aujla, Amandeep
collection PubMed
description B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Inotuzumab ozogamicin (INO), a CD22 antibody conjugated with calicheamicin is one of the newest ADCs. INO has been approved for treatment of relapsed /refractory B cell precursor ALL. Multiple ongoing trials are evaluating its role in the relapsed /refractory B cell NHL. This review summarized recent development in INO applications for ALL and NHL.
format Online
Article
Text
id pubmed-6458768
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64587682019-04-22 Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma Aujla, Amandeep Aujla, Ravijot Liu, Delong Biomark Res Review B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Inotuzumab ozogamicin (INO), a CD22 antibody conjugated with calicheamicin is one of the newest ADCs. INO has been approved for treatment of relapsed /refractory B cell precursor ALL. Multiple ongoing trials are evaluating its role in the relapsed /refractory B cell NHL. This review summarized recent development in INO applications for ALL and NHL. BioMed Central 2019-04-11 /pmc/articles/PMC6458768/ /pubmed/31011424 http://dx.doi.org/10.1186/s40364-019-0160-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Aujla, Amandeep
Aujla, Ravijot
Liu, Delong
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
title Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
title_full Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
title_fullStr Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
title_full_unstemmed Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
title_short Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
title_sort inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-hodgkin lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458768/
https://www.ncbi.nlm.nih.gov/pubmed/31011424
http://dx.doi.org/10.1186/s40364-019-0160-4
work_keys_str_mv AT aujlaamandeep inotuzumabozogamicininclinicaldevelopmentforacutelymphoblasticleukemiaandnonhodgkinlymphoma
AT aujlaravijot inotuzumabozogamicininclinicaldevelopmentforacutelymphoblasticleukemiaandnonhodgkinlymphoma
AT liudelong inotuzumabozogamicininclinicaldevelopmentforacutelymphoblasticleukemiaandnonhodgkinlymphoma

Ejemplares similares